45 unknown. 45 Phase 2, 30 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Unknown 45 |
| Phase 1 | 30 | Unknown 30 |
Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor ZG005 Powder for Injection, Donafenib Tosilate Tablets - Solid Tumor | Phase 1 / Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 130 | 2024-05-10 | 2024-06-14 |
| A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors QLS31905, Nab paclitaxel, Gemcitabine - Solid Tumor | Phase 1 / Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 115 | 2023-10-01 | 2023-09-18 |
| A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours ZG2001 Tosilate Tablets - Solid Tumor, KRAS Mutation-Related Tumors | Phase 1 / Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 110 | 2023-08-10 | 2024-03-06 |
| BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors BPB-101 - Solid Tumor | Phase 1 / Phase 2 | Unknown | Betta Pharmaceuticals Co., Ltd. | 388 | 2023-05-16 | 2023-06-06 |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors Pemigatinib - Solid Tumor, FGF Receptor Gene Mutation | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 20 | 2023-05-01 | 2023-09-01 |
| A Study of RD14-01 in Patients With Advanced Solid Tumors RD14-01 - Solid Tumor | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 12 | 2023-02-08 | 2023-03-01 |
| ALG.APV-527 First-in-human Study ALG.APV-527 - Solid Tumor | Phase 1 / Phase 2 | Unknown | Aptevo Therapeutics | 56 | 2022-12-23 | 2023-07-07 |
| A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation HLX208 - Solid Tumor | Phase 2 | Unknown | Shanghai Henlius Biotech | 30 | 2022-10-20 | 2022-09-06 |
| Safety and Efficacy of RX-af01 Combined With PD-1 Antibody RX-af01, Mixed bacteria, High dose RX-af01 - Solid Tumor, Immune Checkpoint Inhibitor | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 60 | 2022-09-15 | 2024-01-23 |
| Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer Dalpiciclib - Solid Tumor | Phase 2 | Unknown | Hebei Medical University Fourth Hospital | 30 | 2022-09-10 | 2022-08-23 |
| Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas IMM01, Tislelizumab - Solid Tumor, Classic Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 309 | 2022-05-17 | 2023-04-27 |
| An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors Pyrotinib Maleate, standard regimen - Solid Tumor | Phase 2 | Unknown | Zhongshan Hospital Xiamen University | 60 | 2022-03-04 | 2022-03-10 |
| Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors HS-10365 - Solid Tumor | Phase 1 / Phase 2 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 306 | 2021-11-09 | 2023-06-01 |
| A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors GT90001+KN046, GT90001/KN046 - Solid Tumor | Phase 1 / Phase 2 | Unknown | Suzhou Kintor Pharmaceutical Inc, | 216 | 2021-11-02 | 2024-02-09 |
| ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0) ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 - Carcinoma, Solid Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 55 | 2021-11-01 | 2021-11-10 |
| Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements CURATE.AI, Nivolumab, Pembrolizumab - Solid Tumor | Phase 1 / Phase 2 | Unknown | National University Hospital, Singapore | 10 | 2021-08-19 | 2023-03-03 |
| Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors T3011 - Solid Tumor, Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | ImmVira Pharma Co. Ltd | 42 | 2021-08-10 | 2024-03-04 |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors EU101 - Solid Tumor, Renal Cell Cancer Metastatic | Phase 1 / Phase 2 | Unknown | Eutilex | 110 | 2021-05-31 | 2024-03-15 |
| An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma Manganese Chloride, Radiotherapy, Chemo-immunotherapy - Solid Tumor, Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 10 | 2021-05-06 | 2021-05-05 |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor SY-5007 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | Shouyao Holdings (Beijing) Co. LTD | 184 | 2021-04-23 | 2023-04-12 |
Showing 20 of 45. Sign in to see all of them.
Neoplasms (5) · Stomach Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma (3) · Lymphoma (3) · Neoplasm Metastasis (3) · Carcinoma, Renal Cell (2) · Melanoma (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Acrocephalosyndactylia (1) · Anus Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Merkel Cell (1)
Neoplasms (15) · Neoplasms by Histologic Type (11) · Neoplasms by Site (11) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Neoplasms, Glandular and Epithelial (6) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Hemic and Lymphatic Diseases (5) · Lung Diseases (5) · Lung Neoplasms (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5)
pembrolizumab (4) · Injections (3) · Radiotherapy (3) · Capecitabine (2) · Interleukin-2 (2) · Nivolumab (2) · Paclitaxel (2) · SHR-1701 (2) · apatinib (2) · atezolizumab (2) · niraparib (2) · AZD8186 (1) · Alpelisib (1) · Antigens, CD1d (1) · Cannabidiol (1)
Chinese PLA General Hospital (4) · National University Hospital, Singapore (2) · Seoul National University Bundang Hospital (2) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) · Tianjin Medical University Second Hospital (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Altum Pharmaceuticals INC (1) · Aptevo Therapeutics (1) · Asclepius Technology Company Group (Suzhou) Co., Ltd. (1) · Beijing Hospital (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Betta Pharmaceuticals Co., Ltd. (1) · Bio-Thera Solutions (1) · Chungbuk National University Hospital (1) · ENB Therapeutics, Inc (1)
China (25) · United States (8) · South Korea (4) · Singapore (2) · Australia (1) · Belgium (1) · Sweden (1) · Taiwan (1)
Jason Wu (2) · Raghav Sundar (2) · Angela Ogden, MD (1) · Anish Thomas, MD (1) · Atsushi Osada (1) · Baorui Baorui Liu, Doctor (1) · Hadas Lemberg, PhD (1) · HaiTao Wang, Ph.D (1) · Haitao Wang (1) · Hui Wang, MD (1) · Jiayi Chen, MD (1) · Jin Li, PhD (1) · Keun-Wook Lee, MD, PhD (1) · Keun-Wook Lee, MD. & Ph.D (1) · Ki Hyeong Lee, M.D. (1)
PMID 24523121, PMID 26984449, PMID 27053773, PMID 30089632, PMID 30094065, PMID 31771394, PMID 32108102, PMID 33634869, PMID 34713106, PMID 35920783, PMID 37036671, PMID 37056765, PMID 38172595, PMID 38954010, PMID 39489747, PMID 39948624, PMID 42337043, PMID 42542997